Bexarotene (brand name: Targretin) is an antineoplastic (anti-cancer) agent indicated by the U.S.Food and Drug Administration (FDA) (in late 1999) and the European Medicines Agency (EMA) (early 2001) for use as a treatment for cutaneous T cell lymphoma (CTCL).
This page contains content from the copyrighted Wikipedia article "Bexarotene"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
